14,835,146 Shares in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Acquired by Two Seas Capital LP

Two Seas Capital LP acquired a new stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 14,835,146 shares of the biotechnology company’s stock, valued at approximately $7,992,000. Adaptimmune Therapeutics makes up about 0.7% of Two Seas Capital LP’s holdings, making the stock its 20th biggest position. Two Seas Capital LP owned approximately 0.06% of Adaptimmune Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Long Focus Capital Management LLC lifted its stake in shares of Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the period. Rock Springs Capital Management LP lifted its position in Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 58,000 shares during the period. Renaissance Technologies LLC lifted its position in Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after purchasing an additional 869,949 shares during the period. Invesco Ltd. boosted its stake in shares of Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 28,526 shares during the last quarter. Finally, LPL Financial LLC grew its position in shares of Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after buying an additional 94,623 shares during the period. 31.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. HC Wainwright reduced their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. StockNews.com began coverage on Adaptimmune Therapeutics in a report on Tuesday. They issued a “buy” rating for the company. Jones Trading cut Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th. Finally, Scotiabank lowered their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1.83.

Adaptimmune Therapeutics Stock Performance

ADAP stock opened at $0.27 on Friday. Adaptimmune Therapeutics plc has a 1-year low of $0.20 and a 1-year high of $1.48. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The firm has a market cap of $68.58 million, a PE ratio of -1.21 and a beta of 2.84. The business’s 50-day moving average price is $0.36 and its two-hundred day moving average price is $0.56.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. As a group, research analysts forecast that Adaptimmune Therapeutics plc will post -0.14 earnings per share for the current year.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.